Janux Therapeutics logo

Janux Therapeutics Share Price (NASDAQ: JANX)

$22.74

-0.31

(-1.34%)

Last updated on

Check the interactive Janux Therapeutics Stock chart to analyse performance

Janux Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$22.48
    Today's High:$23.39

    Day's Volatility :3.89%

  • 52 Weeks Low:$21.97
    52 Weeks High:$71.71

    52 Weeks Volatility :69.36%

Janux Therapeutics Stock Returns

PeriodJanux Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-9.16%
3.6%
0.0%
6 Months
-28.62%
-7.7%
0.0%
1 Year
-49.52%
-12.6%
0.0%
3 Years
104.5%
9.5%
-4.7%

Janux Therapeutics Inc Key Stats

Check Janux Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$23.05
Open
$23.39
Today's High
$23.39
Today's Low
$22.48
Market Capitalization
$1.4B
Today's Volume
$456.3K
52 Week High
$71.71
52 Week Low
$21.9707
Revenue TTM
$439.0K
EBITDA
$-142.8M
Earnings Per Share (EPS)
$-1.81
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-12.82%

Stock Returns calculator for Janux Therapeutics Stock including INR - Dollar returns

The Janux Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Janux Therapeutics investment value today

Current value as on today

₹53,688

Returns

₹46,312

(-46.31%)

Returns from Janux Therapeutics Stock

₹51,596 (-51.6%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Janux Therapeutics Stock

93%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Janux Therapeutics Stock from India on INDmoney has increased by 93% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Janux Therapeutics Inc

  • Name

    Holdings %

  • RA Capital Management, LLC

    18.87%

  • FMR Inc

    14.98%

  • HHG PLC

    7.52%

  • Adage Capital Partners Gp LLC

    6.16%

  • Paradigm Biocapital Advisors LP

    4.92%

  • BlackRock Inc

    4.85%

Analyst Recommendation on Janux Therapeutics Stock

Rating
Trend

Buy

    93%Buy

    6%Hold

    0%Sell

Based on 15 Wall street analysts offering stock ratings for Janux Therapeutics(by analysts ranked 0 to 5 stars)

Janux Therapeutics Share Price Target

What analysts predicted

Upside of 262.63%

Target:

$82.46

Current:

$22.74

Janux Therapeutics share price target is $82.46, a slight Upside of 262.63% compared to current price of $22.74 as per analysts' prediction.

Janux Therapeutics Stock Insights

  • Price Movement

    In the last 7 days, JANX stock has moved down by -6.5%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 8.89M → -8.51M (in $), with an average decrease of 1067.0% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -20.21M → -33.85M (in $), with an average decrease of 30.2% per quarter
  • JANX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 121.5%
  • JANX vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 7.7%
  • Price to Sales

    ForJANX every $1 of sales, investors are willing to pay $3245.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Janux Therapeutics Technicals Summary

Sell

Neutral

Buy

Janux Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Janux Therapeutics Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Janux Therapeutics Inc logo
-3.57%
-28.62%
-49.52%
104.5%
-18.24%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

Janux Therapeutics Dividend announcements

  • Janux Therapeutics Earnings

    Janux Therapeutics’s price-to-earnings ratio stands at None

About Janux Therapeutics Inc

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.
Organization
Janux Therapeutics
Employees
103
CEO
Dr. David Alan Campbell Ph.D.
Industry
Services

Key Management of Janux Therapeutics Inc

NameTitle
Dr. David Alan Campbell Ph.D.
President, CEO & Director
Dr. Thomas Diraimondo Ph.D.
Chief Scientific Officer
Mr. Byron Robinson J.D., Ph.D.
Chief Strategy Officer
Mr. Matt Whitmire
Vice President of Finance
Ms. Maria Dobek
Principal Accounting Officer & VP of Accounting
Mr. Charles M. Winter
Chief Technical Officer
Mr. James Pennington
General Counsel & Corporate Secretary
Ms. Janeen Doyle
Chief Corporate & Business Development Officer
Mr. Andy Hollman Meyer
Chief Business Officer
Dr. Zachariah McIver D.O., Ph.D.
Chief Medical Officer

Important FAQs about investing in JANX Stock from India :

What is Janux Therapeutics share price today?

Janux Therapeutics share price today is $22.74 as on at the close of the market. Janux Therapeutics share today touched a day high of $23.39 and a low of $22.48.

What is the 52 week high and 52 week low for Janux Therapeutics share?

Janux Therapeutics share touched a 52 week high of $71.71 and a 52 week low of $21.97. Janux Therapeutics stock price today i.e. is closed at $22.74, lower by 68.29% versus the 52 week high.

How to invest in Janux Therapeutics Stock (JANX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Janux Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Janux Therapeutics Shares that will get you 0.0660 shares as per Janux Therapeutics share price of $22.74 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Janux Therapeutics Stock (JANX) from India?

Indian investors can start investing in Janux Therapeutics (JANX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Janux Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Janux Therapeutics share’s latest price of $22.74 as on August 30, 2025 at 1:29 am IST, you will get 0.4398 shares of Janux Therapeutics. Learn more about fractional shares .

What are the returns that Janux Therapeutics has given to Indian investors in the last 5 years?

Janux Therapeutics stock has given -18.24% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?